Heptares to Present at BIO-Europe 2012
WELWYN GARDEN CITY, England and BOSTON, November 8, 2012 /PRNewswire/ –
Heptares Therapeutics, the leading GPCR drug discovery company, announces that its
Chief Executive Officer, Malcolm Weir, will present the Company at BIO-Europe 2012
[http://www.ebdgroup.com/bioeurope/index.php ], the international partnering conference,
which takes place at the CCH Congress Center, Hamburg, Germany (12-14 November 2012).
Dr Weir’s presentation will be at 2:15pm (CET)on Tuesday 13 November in Room B1, Level
About Heptares Therapeutics
Heptares discovers and develops new medicines targeting GPCRs (Gprotein-coupled
receptors), a super-family of drug targets linked to a wide range of human diseases. Our
pharmaceutical partners include Shire, AstraZeneca, MedImmune and Takeda, and we have
raised $40M from MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and
Heptares is pioneering the application of structure-based drug design to the GPCR
super-family of targets and is focused on creating molecules that modulate high-value, yet
historically undruggable or challenging, GPCRs. Our platform incorporates proprietary
technologies for engineering stabilised GPCRs in their natural pharmacological
conformations, identifying previously unknown chemistries for GPCR protein-drug
interactions, and deploying advanced fragment-based approaches to GPCR target space for
the first time.
Using this approach, we have generated a broad pipeline of drug candidates for the
treatment of serious disorders, including Alzheimer’s disease, Parkinson’s disease,
schizophrenia, depression, chronic insomnia, addiction disorders, migraine and diabetes.
For more information about Heptares, please visit http://www.heptares.com.
SOURCE Heptares Therapeutics